Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected Sarcomas

NCT04968106 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT04968106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04968106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected Sarcomas
Lead sponsor
Institut Bergonié
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 7, 2022
Completion date
April 30, 2028
Enrollment
66 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

resectable sarcoma